Sclerostin exerts a direct anti-anabolic action on bone tissue by binding low-density lipoprotein-receptor-related protein (LRP4); in fact, some cases of sclerosteosis are caused by mutations in this protein [39]. Here, SOST is linked to sclerosteosis.